Development of novel anticancer drug by functionalized hybrid peptide
| Project/Area Number |
26860103
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Aoyama Gakuin University (2015-2016)
Kyoto University (2014) |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HORIBE TOMOHISA 京都大学, 大学院医学研究科, 特定准教授 (20467468)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | ペプチド / DDS / 癌 / ペプチド創薬 / 分子標的 / デンドリマー |
|---|
| Outline of Final Research Achievements |
Cancer has become a common disease that causes the death of human in recent years. From the past decades until now, various anticancer agents have been developed to overcome cancer. Peptides are highly selective and efficacious molecules that can bind to specific cell surface receptors. Due to these reasons, many types of peptides have been created to act as anticancer drugs. However, the stability of peptide drugs is limited because they can be degraded easily by proteases and opsonization process occurring in vivo. Hybrid peptides that contain specific target binding (EGRF) and cell-killing components could increase efficiency of cancer destruction. However, the half-life of hybrid peptides in serum is very short due to enzymatic degradation. To escape from this degradation, we demonstrated the new formulation of hybrid peptides by using modifying the hybrid peptide with polyethylene glycol (PEG). PEG could bind to hybrid peptide through a MMP2-cleavable linker.
|
Report
(4 results)
Research Products
(6 results)
